MVM invests in MDxHealth SA

In May 2020, MVM closed a growth investment in MDxHealth SA, a company that markets proprietary, differentiated tests that optimize the care of patients with prostate cancer. MDxHealth’s two commercial tests, SelectMDx and ConfirmMDx, improve patient care and reduce costs by helping clinicians avoid unnecessary prostate biopsies.

MDxHealth will appoint Eric Bednarski as director of the company and Kyle Dempsey will join as a board observer.

Latest News

MVM Winter 2020 Newsletter

Recent updates regarding MVM team, new investments, and portfolio.

MVM invests in GT Medical

MVM led the Series B financing of GT Medical Technologies, a company dedicated to improving the lives of patients with brain tumors.

Valneva announces major COVID-19 vaccine partnership with UK government

UK government invests in Valneva's manufacturing facility and secures supply of 60 million doses of Valneva's inactivated COVID-19 vaccine VLA2001, with option for another 130 million doses.

MVM Summer 2020 Newsletter

Recent updates regarding MVM team, new investments, and portfolio.

MVM invests in Paragon 28

MVM co-led the Series B financing of Paragon 28, a leading orthopedic foot and ankle company.

Valneva confirms participation in UK government COVID-19 vaccine response program

Valneva has reached agreement in principle with the UK government to provide up to 100 million doses of its SARS-CoV-2 vaccine candidate.